Dermata Therapeutics Inc
DRMA2.370USD
+0.330+16.18%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.00MMarket Cap
0.16P/E TTM
More Details of Dermata Therapeutics Inc Company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Dermata Therapeutics Inc Info
Ticker SymbolDRMA
Company nameDermata Therapeutics Inc
IPO dateAug 13, 2021
CEOProehl (Gerald T)
Number of employees8
Security typeOrdinary Share
Fiscal year-endAug 13
Address3525 Del Mar Heights Rd., #322
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18582230882
Websitehttps://www.dermatarx.com/
Ticker SymbolDRMA
IPO dateAug 13, 2021
CEOProehl (Gerald T)
Company Executives of Dermata Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
8.15K
--
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
7.87K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.00
--
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.00
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
12.00
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
11.00
--
Mr. Cliff Mastricola
Mr. Cliff Mastricola
Investor Relations
Investor Relations
--
--
Dr. Maria Bedoya Toro Munera, Ph.D.
Dr. Maria Bedoya Toro Munera, Ph.D.
Senior Vice President - Regulatory Affairs & Quality Assurance
Senior Vice President - Regulatory Affairs & Quality Assurance
--
--
Ms. Mary M. Fisher
Ms. Mary M. Fisher
Independent Director
Independent Director
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
8.15K
--
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
7.87K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.00
--
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.00
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
12.00
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
11.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.95%
Proehl Investment Ventures LLC
7.79%
Fisher (Mary)
1.92%
UBS Financial Services, Inc.
0.98%
Hale (David F)
0.79%
Other
80.56%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.95%
Proehl Investment Ventures LLC
7.79%
Fisher (Mary)
1.92%
UBS Financial Services, Inc.
0.98%
Hale (David F)
0.79%
Other
80.56%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.00%
Corporation
7.79%
Individual Investor
3.50%
Investment Advisor
0.98%
Research Firm
0.01%
Other
79.73%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
15
92.23K
5.00%
--
2025Q3
15
92.23K
7.53%
+41.42K
2025Q2
17
50.82K
8.21%
-1.04K
2025Q1
16
51.85K
1.03%
+45.65K
2024Q4
20
5.39K
0.75%
+4.75K
2024Q3
21
645.00
2.73%
-2.63K
2024Q2
22
3.28K
1.86%
+2.77K
2024Q1
22
503.00
5.63%
-2.00K
2023Q4
24
2.04K
5.42%
+1.34K
2023Q3
28
700.00
7.51%
-258.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
32.22K
4.73%
-8.88K
-21.61%
Jun 30, 2025
Proehl Investment Ventures LLC
79.95K
11.73%
--
--
May 16, 2025
Fisher (Mary)
19.70K
2.89%
--
--
May 16, 2025
UBS Financial Services, Inc.
9.10K
1.33%
+2.07K
+29.41%
Jun 30, 2025
Hale (David F)
8.15K
1.2%
--
--
May 16, 2025
Van Hoose (Kyri K)
7.87K
1.16%
--
--
May 16, 2025
Tower Research Capital LLC
532.00
0.08%
+352.00
+195.56%
Jun 30, 2025
Proehl (Gerald T)
110.00
0.02%
--
--
May 16, 2025
SBI Securities Co., Ltd.
101.00
0.01%
+1.00
+1.00%
Jun 30, 2025
Wierenga (Wendell)
26.00
0%
--
--
May 16, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 30, 2025
Merger
10→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
Mar 13, 2023
Merger
16→1
Date
Type
Ratio
Jul 30, 2025
Merger
10→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
May 14, 2024
Merger
15→1
Mar 13, 2023
Merger
16→1
Mar 13, 2023
Merger
16→1
Mar 13, 2023
Merger
16→1
Mar 13, 2023
Merger
16→1
FAQs
Who are the top five shareholders of Dermata Therapeutics Inc?
The top five shareholders of Dermata Therapeutics Inc are:
Armistice Capital LLC holds 32.22K shares, accounting for 4.73% of the total shares.
Proehl Investment Ventures LLC holds 79.95K shares, accounting for 11.73% of the total shares.
Fisher (Mary) holds 19.70K shares, accounting for 2.89% of the total shares.
UBS Financial Services, Inc. holds 9.10K shares, accounting for 1.33% of the total shares.
Hale (David F) holds 8.15K shares, accounting for 1.20% of the total shares.
Armistice Capital LLC holds 32.22K shares, accounting for 4.73% of the total shares.
Proehl Investment Ventures LLC holds 79.95K shares, accounting for 11.73% of the total shares.
Fisher (Mary) holds 19.70K shares, accounting for 2.89% of the total shares.
UBS Financial Services, Inc. holds 9.10K shares, accounting for 1.33% of the total shares.
Hale (David F) holds 8.15K shares, accounting for 1.20% of the total shares.
What are the top three shareholder types of Dermata Therapeutics Inc?
The top three shareholder types of Dermata Therapeutics Inc are:
Armistice Capital LLC
Proehl Investment Ventures LLC
Fisher (Mary)
Armistice Capital LLC
Proehl Investment Ventures LLC
Fisher (Mary)
How many institutions hold shares of Dermata Therapeutics Inc (DRMA)?
As of 2025Q4, 15 institutions hold shares of Dermata Therapeutics Inc, with a combined market value of approximately 92.23K, accounting for 5.00% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.53%.
What is the biggest source of revenue for Dermata Therapeutics Inc?
In --, the -- business generated the highest revenue for Dermata Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
